IL6 and myeloid sarcoma: Using ROC analysis, wecalculated area under the curve (AUC) values and determined cut-off values ofCSF IL-6 and of serum IL-8, GRO-α, APRIL and MIP-1β to discriminate AQP4-Ab,MOG-Ab and NMDAR-Ab from MS patients with 95% specificity (Figure 4, Table 1) Serum IL-8 level ≥3.7 pg/mlhad the highest sensitivity (77%) for AQP4-Ab and MOG-Ab-associateddemyelinating diseases, followed by serum GRO-α (cut-off ≥7.2 pg/ml, sensitivity70%) and CSF IL-6 (cut-off ≥17.6 pg/ml, sensitivity 47%).